登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C16H24N2O2 · HCl
化学文摘社编号:
分子量:
312.83
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
InChI
1S/C16H24N2O2.ClH/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18;/h12,17H,3-10H2,1-2H3;1H
SMILES string
CCC1=C(C)NC2=C1C(C(CN3CCOCC3)CC2)=O.Cl
InChI key
GQWNECFJGBQMBO-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
solid
color
off-white
solubility
H2O: 19 mg/mL
originator
Endo
Quality Level
Gene Information
human ... DRD2(1813), HTR2A(3356), MAOA(4128), MAOB(4129)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
D2 dopamine receptor antagonist; MAO inhibitor.
Features and Benefits
This compound was developed by Endo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Danger
hcodes
pcodes
Hazard Classifications
Acute Tox. 3 Oral
存储类别
6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
法规信息
新产品
此项目有
Jennifer Dugan Stocks et al.
Journal of child and adolescent psychopharmacology, 22(2), 102-111 (2012-03-01)
To evaluate safety and tolerability of four doses of immediate-release molindone hydrochloride in children with attention-deficit/hyperactivity disorder (ADHD) and serious conduct problems. This open-label, parallel-group, dose-ranging, multicenter trial randomized children, aged 6-12 years, with ADHD and persistent, serious conduct problems
Unilateral auditory hallucinations in a boy with ipsilateral conductive hearing loss.
J R Brasic et al.
Journal of neurology, neurosurgery, and psychiatry, 62(3), 302-302 (1997-03-01)
T Baptista et al.
Pharmacopsychiatry, 35(6), 205-219 (2003-01-09)
Excessive body weight gain (BWG) is a common side effect of some typical and atypical antipsychotic drugs (APs). Convergent evidence suggests a hierarchy in the magnitude of BWG that may be induced by diverse agents, being very high for clozapine
Could repetitive transcranial magnetic stimulation improve neurocognition in early-onset schizophrenia spectrum disorders?
Paul E Croarkin et al.
Journal of the American Academy of Child and Adolescent Psychiatry, 51(9), 949-951 (2012-08-25)
C Recasens
L'Encephale, 27(3), 269-276 (2001-08-08)
Weight gain associated with neuroleptics or antipsychotic treatment is well known by psychiatrists, but is too rarely considered as justifying a specific treatment program. Overweight is a risk factor for somatic disorders and can have a negative influence on self-esteem
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持